OCT 06, 2016 12:00 PM PDT

The Clinical and Economic Impact of Precision Cancer Medicine

Speaker
  • Executive Director of Precision Medicine & Precision Genomics, Intermountain Healthcare
    Biography
      Dr. Lincoln Nadauld, MD, PhD, is the Executive Director of Precision Medicine and Precision Genomics at Intermountain Healthcare, an integrated healthcare system located in the Intermountain West. Dr. Nadauld completed clinical training in Medical Oncology at Stanford University School of Medicine, where he is still part of the research faculty focusing on cancer genomics and personalized cancer medicine. Dr. Nadauld oversees the clinical implementation of genomics cancer medicine across Intermountain Healthcare's 22 hospitals and 180 physician clinics. In his spare time Dr. Nadauld enjoys attending his children's sporting events, water sports, fishing and athletics.

    Abstract

    Precision medicine is a rapidly evolving paradigm powered by emerging technological, diagnostic, and pharmacological capabilities.  The clinical application of precision medicine holds promise across medical disciplines, and has become increasingly prominent in advanced cancer patients where genomic analyses can readily identify actionable somatic variants.  In spite of the clinical potential of precision cancer medicine, widespread implementation has been limited, largely due to the paucity of robust clinical experience in the space.  Leveraging the unique aspects of a large, integrated health delivery network, we have clinically implemented a comprehensive precision medicine program for advanced cancer patients.  We outline the Precision Cancer Genomics Program at Intermountain Healthcare, and provide insights into the successes, challenges and economic impact associated with the de novo implementation of an enterprise-wide precision medicine program.
     


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    C.E. CREDITS
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    Loading Comments...
    Show Resources